Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celsion gets US nod for prostate cancer trial:

This article was originally published in Clinica

Executive Summary

Celsion has gained the go-ahead from the US FDA to begin clinical trials of its heat-activated drug treatment for prostate cancer. The therapy combines a focused-heat thermotherapy delivery system with a heat-sensitive liposome that is designed, when activated, to deliver a chemotherapeutic agent to the targeted tumour site. Celsion, of Columbia, Maryland has exclusive worldwide commercial licences to the heat-activated liposome technology, which was invented by Dr David Needham from Duke University in Durham, North Carolina.

You may also be interested in...



US Medicare Agency Alters Payments For Use Of Telehealth Tech, Lab Specimen Collection For COVID-19

An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.

Vaccine Experts Inject Realism Into US Gov't's COVID-19 Timeline

The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval. 

Trump Pushes Back On OIG Report That Hospitals Want Feds To Better Police Resources, Relax Regs

When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.

Topics

UsernamePublicRestriction

Register

MT067130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel